Today, the problem of menopausal syndrome (MS) remains relevant for many reasons: increased life expectancy, active social life in a given period of time, decreased quality of life, including physical health, emotional well-being and social aspects. Modern medicine offers new methods of treating and supporting women during menopause, which increases interest in studying and improving the management of menopausal syndrome (MS). MS and genitourinary menopausal syndrome (GUMS) are closely related, because both are a consequence of a decrease in estrogen levels in a woman’s body during menopause. GUMS refers to symptoms that affect the genital area, urinary tract, and bladder. Problems such as vaginal dryness, discomfort during sexual intercourse, frequent urination and recurring urinary infections develop. The most significant urological problem is urinary incontinence, which has not only medical but also social significance and negatively affects the quality of life. The most effective drug therapy for GUMS in women is local estrogen therapy in combination with combined oral menopausal hormone therapy (MHT). Replenishing the deficiency of vitamins and elements involved in metabolic processes is of great importance. Metabolic therapy can be considered not only as an alternative treatment, but also as an additional therapy while taking MHT drugs, which significantly improves the results of treatment. In order to eliminate the symptoms of an overactive bladder, it is possible to prescribe trospium chloride (Spazmex®), taking into account contraindications.

Keywords: genitourinary menopausal syndrome, vitamin C, selenium, menopausal hormone therapy, zinc, menopausal syndrome, trospium chloride, vitamin A, metabolic therapy, urinary incontinence, vitamin E